Increased risk for the development of prostatic hyperplasia in older patients. Exclude prostatic cancer or risk of pre-existing prostatic cancer before starting therapy. May accelerate development of sub-clinical prostatic cancer & benign prostatic hyperplasia. Perform regular check-ups of the prostate gland & breast. Monitor testosterone level at baseline & at regular intervals during treatment. Regularly monitor Hb, haematocrit, liver function & blood lipid profile. Patients at risk of hypercalcemia (& associated hypercalciuria) eg, due to bone metastasis; patients w/ acquired or inherited bleeding disorders; thrombophilia; severe cardiac, hepatic, or renal insufficiency or ischaemic heart disease; pre-existing HTN; impaired renal or hepatic function; epilepsy or migraine; patients pre-disposed to oedema; diabetic patients. Reports of venous thromboembolic events, including DVT & pulmonary embolism; benign & malignant liver tumors. Permanently discontinue if symptoms of excessive androgen exposure persist or recur during therapy on the recommended dosing schedule. May accelerate bone maturation in childn. Not suitable for treatment of male sterility. Pre-existing sleep apnea may be potentiated. Positive results in doping tests. Not for enhancing muscular development or increasing physical ability. Concomitant use w/ coumarin-derived anticoagulants. May reversibly reduce spermatogenesis. Elderly >65 yr.